首页> 美国卫生研究院文献>Scientific Reports >TGF-β concentrations and activity are down-regulated in the aqueous humor of patients with neovascular age-related macular degeneration
【2h】

TGF-β concentrations and activity are down-regulated in the aqueous humor of patients with neovascular age-related macular degeneration

机译:新血管性年龄相关性黄斑变性患者房水中TGF-β的浓度和活性下调

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Controversy still exists regarding the role of the TGF-β in neovascular age-related macular degeneration (nAMD), a major cause of severe visual loss in the elderly in developed countries. Here, we measured the concentrations of active TGF-β1, TGF-β2, and TGF-β3 by ELISA in the aqueous humor of 20 patients affected by nAMD, who received 3 consecutive monthly intravitreal injections of anti-VEGF-A antibody. Samples were collected at baseline (before the first injection), month 1 (before the second injection), and month 2 (before the third injection). The same samples were used in a luciferase-based reporter assay to test the TGF-β pathway activation. Active TGF-β1 concentrations in the aqueous humor were below the minimum detectable dose. Active TGF-β2 concentrations were significantly lower at baseline and at month 1, compared to controls. No significant differences in active TGF-β3 concentration were found among the sample groups. Moreover, TGF-β pathway activation was significantly lower at baseline compared to controls. Our data corroborate an anti-angiogenic role for TGF-β2 in nAMD. This should be considered from the perspective of a therapy using TGF-β inhibitors.
机译:关于TGF-β在新生血管性年龄相关性黄斑变性(nAMD)中的作用仍存在争议,后者是发达国家老年人严重视力丧失的主要原因。在这里,我们通过ELISA测量了20名受nAMD影响的患者房水中的活性TGF-β1,TGF-β2和TGF-β3的浓度,这些患者连续3个月每月接受玻璃体内注射抗VEGF-A抗体。在基线(第一次注射之前),第一个月(第二次注射之前)和第二个月(第三次注射之前)收集样品。将相同的样品用于基于萤光素酶的报告基因检测中,以测试TGF-β途径的激活。房水中的活性TGF-β1浓度低于最小可检测剂量。与对照组相比,基线和第1个月的活跃TGF-β2浓度明显降低。样品组之间的活性TGF-β3浓度没有显着差异。此外,与对照组相比,基线时TGF-β途径的活化显着降低。我们的数据证实了nAMD中TGF-β2的抗血管生成作用。应该从使用TGF-β抑制剂的疗法的角度考虑这一点。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号